| abstract |
Disclosed is a polymorph type II crystal of 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide. A powder X-ray diffraction spectrum including peaks of 6.5 (± 0.2), 9.9, 15.0, and 17.0 degrees 2θ, and 20,23- having a melting point of 113 to 119 ° C. Solvated and unsolvated crystalline forms of dipiperidinyl-5-O-mycaminosyl-tylonolide and methods for making such crystalline forms. A drug comprising the crystalline form, a method for producing a drug comprising the crystalline form, a therapeutic method using the crystalline form, and a kit comprising the crystalline form. [Selection figure] None |